pharmaphorum3d
Kite and Sangamo come together in $3bn cancer gene editing alliance
Gilead pounced to buy cell therapy company Kite in August last year for just under $12 billion, shortly before the biotech firm gained approval for its CAR-T cancer therapy Yescarta. Now Gilead is ...
pharmaphorum7d
Kite and Fosun appoint leader for CAR-T debut in China
Richard Wang has been named as chief executive of the joint venture, named Fosun Kite Biotechnology. Wang has extensive experience in the industry including roles at Procter & Gamble ...
The Pharma Letter10d
BRIEF—Kite shares new data on CAR T cell therapy
Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...
The Pharma Letter10d
Driving innovation in blood cancer: Gilead and Kite Oncology’s vision for the Middle East
Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...
Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting
Sartorius Stedim Biotech SA / Key word (s): Dividend Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting 07-Feb-2025 ...